ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Prevalence and Severity of Sleep Apnea in Men with High Hematocrit on TRT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 223321" data-attributes="member: 13851"><p><strong>Prevalence and Severity of Obstructive Sleep Apnea in Men with Polycythemia on Testosterone Therapy (2022)</strong></p><p><em>CSalter, JMFFlores, ESchofield, MTan, JMulhall</em></p><p></p><p></p><p><strong>Introduction</strong></p><p></p><p><em>Polycythemia is independently associated with both testosterone therapy (TTH) and obstructive sleep apnea (OSA).</em></p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em><strong>The purpose of this study was to evaluate the prevalence and severity of OSA in men who experience polycythemia while on TTH.</strong></em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em><strong>The study population included men who had polycythemia [hematocrit (HCT) >50%] while on TTH for TD, with total and free T levels within the normal range. </strong>Men completed screening questionnaires for OSA and daytime sleepiness, respectively: STOP-BANG (SB, range 0-8) and the Epworth Sleepiness Scale (ESS, range 0-24). Men whose scores demonstrated intermediate to high risk of OSA proceeded to a diagnostic sleep study which recorded the following parameters: apnea hypoxia index (AHI, normal <5 events/h), total duration SpO2 saturation <88%, and SpO2 nadir. Descriptive statistics are presented</em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em>73 men had a mean age of 60±11.5 years.<strong> Mean HCT pre-TTH and on TTH were 45±3% and 52±1.5%, respectively, for a mean increase of 6.6±3.6%.</strong> <strong>Mean on-treatment total T level 686±285 ng/dL. </strong></em><strong><em>The Median STOP-BANG score was 4 (IQR 3-5), median ESS score was 5 (IQR 3-9). 63% of patients screened positive for OSA on questionnaires. 81% of sleep studies confirmed OSA; the mean AHI of the group was 15.4±13.2 events/hour (range 1.6-54.6 events/hour). 36% of men had AHI≥15 events/hour and 14% ≥30 AHI events/hour. Mean SpO2 nadir was 83±5% (range 69%-93%). 67% of men with OSA had an oxygen nadir in the 80s, 19% in the 70s, and 3% in the 60s. Total duration of hypoxia (SpO2 ≤88%) was 32±50 minutes (range 0.1-202 minutes), 46% of men having hypoxia <10 minutes, 8% 10-20 minutes, 19% 70-150 minutes.</em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><em>Men on TTH who are eugonadal that experience polycythemia have high rates of OSA. 80% of the patients undergoing sleep study had OSA. These data suggest that men with polycythemia on TTH should be screened for OSA.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 223321, member: 13851"] [B]Prevalence and Severity of Obstructive Sleep Apnea in Men with Polycythemia on Testosterone Therapy (2022)[/B] [I]CSalter, JMFFlores, ESchofield, MTan, JMulhall[/I] [B]Introduction[/B] [I]Polycythemia is independently associated with both testosterone therapy (TTH) and obstructive sleep apnea (OSA).[/I] [B]Objective[/B] [I][B]The purpose of this study was to evaluate the prevalence and severity of OSA in men who experience polycythemia while on TTH.[/B][/I] [B]Methods[/B] [I][B]The study population included men who had polycythemia [hematocrit (HCT) >50%] while on TTH for TD, with total and free T levels within the normal range. [/B]Men completed screening questionnaires for OSA and daytime sleepiness, respectively: STOP-BANG (SB, range 0-8) and the Epworth Sleepiness Scale (ESS, range 0-24). Men whose scores demonstrated intermediate to high risk of OSA proceeded to a diagnostic sleep study which recorded the following parameters: apnea hypoxia index (AHI, normal <5 events/h), total duration SpO2 saturation <88%, and SpO2 nadir. Descriptive statistics are presented[/I] [B]Results[/B] [I]73 men had a mean age of 60±11.5 years.[B] Mean HCT pre-TTH and on TTH were 45±3% and 52±1.5%, respectively, for a mean increase of 6.6±3.6%.[/B] [B]Mean on-treatment total T level 686±285 ng/dL. [/B][/I][B][I]The Median STOP-BANG score was 4 (IQR 3-5), median ESS score was 5 (IQR 3-9). 63% of patients screened positive for OSA on questionnaires. 81% of sleep studies confirmed OSA; the mean AHI of the group was 15.4±13.2 events/hour (range 1.6-54.6 events/hour). 36% of men had AHI≥15 events/hour and 14% ≥30 AHI events/hour. Mean SpO2 nadir was 83±5% (range 69%-93%). 67% of men with OSA had an oxygen nadir in the 80s, 19% in the 70s, and 3% in the 60s. Total duration of hypoxia (SpO2 ≤88%) was 32±50 minutes (range 0.1-202 minutes), 46% of men having hypoxia <10 minutes, 8% 10-20 minutes, 19% 70-150 minutes.[/I] Conclusions [I]Men on TTH who are eugonadal that experience polycythemia have high rates of OSA. 80% of the patients undergoing sleep study had OSA. These data suggest that men with polycythemia on TTH should be screened for OSA.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Prevalence and Severity of Sleep Apnea in Men with High Hematocrit on TRT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top